A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer

Ryan J. Brisson, Sara Kochanny, Saba Arshad, Allison Dekker, Jonas A. DeSouza, Vassiliki Saloura, Everett E. Vokes, Tanguy Y. Seiwert

Research output: Contribution to journalArticle

Abstract

Background: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Methods: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. Results: Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. Conclusion: Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Phosphatidylinositol 3-Kinases
Maximum Tolerated Dose
Cetuximab
NVP-BKM120

Keywords

  • advanced disease
  • buparlisib
  • cetuximab
  • head and neck squamous cell carcinoma
  • metastatic disease
  • PI3K inhibitor
  • recurrent disease

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. / Brisson, Ryan J.; Kochanny, Sara; Arshad, Saba; Dekker, Allison; DeSouza, Jonas A.; Saloura, Vassiliki; Vokes, Everett E.; Seiwert, Tanguy Y.

In: Head and Neck, 01.01.2019.

Research output: Contribution to journalArticle

Brisson, Ryan J. ; Kochanny, Sara ; Arshad, Saba ; Dekker, Allison ; DeSouza, Jonas A. ; Saloura, Vassiliki ; Vokes, Everett E. ; Seiwert, Tanguy Y. / A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. In: Head and Neck. 2019.
@article{06893c4b0f1a4b988d138f7a5c906d8b,
title = "A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer",
abstract = "Background: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Methods: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. Results: Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. Conclusion: Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.",
keywords = "advanced disease, buparlisib, cetuximab, head and neck squamous cell carcinoma, metastatic disease, PI3K inhibitor, recurrent disease",
author = "Brisson, {Ryan J.} and Sara Kochanny and Saba Arshad and Allison Dekker and DeSouza, {Jonas A.} and Vassiliki Saloura and Vokes, {Everett E.} and Seiwert, {Tanguy Y.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hed.25910",
language = "English (US)",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer

AU - Brisson, Ryan J.

AU - Kochanny, Sara

AU - Arshad, Saba

AU - Dekker, Allison

AU - DeSouza, Jonas A.

AU - Saloura, Vassiliki

AU - Vokes, Everett E.

AU - Seiwert, Tanguy Y.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Methods: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. Results: Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. Conclusion: Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.

AB - Background: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Methods: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. Results: Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. Conclusion: Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.

KW - advanced disease

KW - buparlisib

KW - cetuximab

KW - head and neck squamous cell carcinoma

KW - metastatic disease

KW - PI3K inhibitor

KW - recurrent disease

UR - http://www.scopus.com/inward/record.url?scp=85071747389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071747389&partnerID=8YFLogxK

U2 - 10.1002/hed.25910

DO - 10.1002/hed.25910

M3 - Article

C2 - 31486207

AN - SCOPUS:85071747389

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

ER -